Health Economics›Urothelial carcinoma›Locally advanced or metastatic disease first-line platinum-eligible

Locally advanced or metastatic disease first-line platinum-eligible

Urothelial carcinoma · 18 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Durvalumab and Tremelimumab Variant #01 Partial	—	R 131 701	28d	—	15.1 mo	2	R 263 402 PFS proxy	1
Carboplatin and Gemcitabine (GCb) and Pembrolizumab Variant #01	—	R 86 402	21d	8.3 mo	17.0 mo	35	R 3 024 057 PFS proxy	2
Cisplatin and Gemcitabine (GC) and Pembrolizumab Variant #01	—	R 85 626	21d	8.3 mo	17.0 mo	36	R 2 992 297 PFS proxy	2
Enfortumab vedotin and Pembrolizumab Variant #01 Partial	—	R 81 987	21d	12.5 mo	32.7 mo	2	R 163 974 PFS proxy	4
Carboplatin and Gemcitabine (GCb) and Atezolizumab Variant #01	—	R 35 669	21d	—	16.0 mo	2	R 71 338 PFS proxy	1
Cisplatin and Gemcitabine (GC) and Atezolizumab Variant #01	—	R 35 040	21d	—	16.0 mo	2	R 70 080 PFS proxy	1
Cisplatin and Gemcitabine (GC) and Bevacizumab Variant #01	—	R 34 213	21d	—	14.5 mo	7	R 235 264 PFS proxy	1
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	—	15.7 mo	2	R 62 509 PFS proxy	1
MVAC Variant #02	—	R 5 442	28d	—	15.1 mo	2	R 10 883 PFS proxy	3
Gemcitabine and Paclitaxel Variant #01	—	R 5 224	21d	—	~7.8 mo	~6	~R 31 344 PFS proxy · indirect	—
PGC Variant #01	—	R 4 667	21d	—	15.8 mo	4	R 18 668 PFS proxy	1
Carboplatin and Gemcitabine (GCb) Variant #01	—	R 4 414	21d	6.3 mo	15.9 mo	2	R 8 829 PFS proxy	9
Cisplatin and Gemcitabine (GC) Variant #01	—	R 3 933	21d	6.4 mo	14.3 mo	6	R 23 595 PFS proxy	13
Cisplatin and Gemcitabine (GC) and Nivolumab Variant #01 Partial	—	R 3 785	21d	7.9 mo	21.7 mo	22	R 22 713 PFS proxy	2
MVAC, dose-dense Variant #01	—	R 2 481	14d	—	17.1 mo	3	R 7 442 PFS proxy	1
CISCA Variant #02	—	R 1 258	21d	—	—	~6	~R 7 550 indirect	—
Carboplatin and Paclitaxel (CP) Variant #02	—	R 1 025	21d	—	13.8 mo	9	R 9 222 PFS proxy	—
Cisplatin monotherapy Variant #01	—	R 588	21d	~2.1 mo	~8.7 mo	~2	~R 1 177 PFS proxy · indirect	8

18 of 18 regimens shown